Simultaneous inhibition of FXR and TGR5 exacerbatess atherosclerotic formation

Shinobu Miyazaki-Anzai,* Masashi Masuda,* Shohei Kohno,* Moshe Levi,*† Yuji Shiozaki,* Audrey L. Keenan,* and Makoto Miyazaki1,*

Division of Renal Diseases and Hypertension,* Department of Medicine, University of Colorado Denver, Aurora, CO 80045; and Department of Biochemistry and Molecular & Cellular Biology†, Georgetown University, Washington, DC 200072

Abstract Simultaneous activation of bile acid receptors farnesoid X receptor (FXR) and G protein-coupled bile acid receptor 1 (TGR5) by INT-767 significantly reduces atherosclerotic formation. In this study, we investigated the effect of simultaneous inactivation of these bile acid receptors in atherosclerosis and which bile acid receptor mediates the anti-atherogenic effect of INT-767. To investigate the role of simultaneous inactivation of FXR and TGR5 in vivo, we generated LDL receptor knockout (LDLR) KO mice with FXR and TGR5 dual deficiency, which exhibited severe atherosclerosis and aortic inflammation through nuclear factor KB activation. The lipid-lowering effects of INT-767 were completely blocked by FXR single deficiency but not TGR5 single deficiency. INT-767 was able to block atherosclerotic formation and decrease levels of aortic cytokines and chemokines in LDLR KO mice under either FXR or TGR5 single deficiency. Dual deficiency of FXR and TGR5 completely blocked the anti-atherogenic and anti-inflammatory effects of INT-767 in LDLR KO mice. We demonstrated that 1) FXR and TGR5 dual deficiency exacerbated the development of atherosclerosis and 2) the anti-atherogenic effect of INT-767 requires the anti-inflammatory effect but not the lipid-lowering effect through the simultaneous activation of FXR and TGR5.

Our results indicate that dual activation of FXR and TGR5 is a promising strategy for treating atherosclerosis.—Miyazaki-Anzai, S., M. Masuda, S. Kohno, M. Levi, Y. Shiozaki, A. L. Keenan, and M. Miyazaki. J. Lipid Res. 2018. 59: 1709–1713.

Supplementary key words atherosclerosis • bile acid • inflammation

INT-767 is a potent dual activator for farnesoid X receptor (FXR) and G protein-coupled bile acid receptor 1 (TGR5), which are two major receptors responsible for bile acid signaling (1). A number of recent reports showed beneficial effects of INT-767 on cardiovascular and metabolic diseases (2–8). Because administration of several FXR-specific or TGR5-specific molecules showed similar beneficial effects on atherosclerosis (9–12), we studied whether simultaneous activation of both FXR and TGR5 is required for the beneficial effects of INT-767.

FXR is selectively expressed in the liver, kidneys, and intestines (13), while TGR5 is mainly expressed in the intestines and immune cells, including macrophages (14). Many lines of evidence have demonstrated that activation of FXR by FXR-specific agonists inhibits the development of atherosclerosis, possibly through a potent lipid-lowering effect (10, 11, 15). TGR5 activation by TGR5-specific agonists such as INT-777 also significantly blocked atherosclerotic formation in LDLR KO mice through the inhibition of NF-κB-mediated macrophage inflammation (12). Contrarily, either FXR or TGR5 deficiency did not significantly aggravate atherosclerosis in LDLR KO mice, suggesting that loss of one bile receptor was compensated for by the other receptor (12, 16).

We previously reported that INT-767 administration significantly blocked atherosclerotic formation in ApoE KO and LDLR KO mice (4), which was recently confirmed by another group (7). In addition, INT-767 treatment showed potent lipid-lowering effects and anti-inflammatory effects (4). In this study, we examined 1) which bile acid receptor mediates the anti-atherogenic, lipid-lowering, and anti-inflammatory effects of INT-767, 2) whether the lipid-lowering effect, anti-inflammatory effect, or both is required for the anti-atherogenic effect of INT-767, and 3) whether simultaneous inhibition of FXR and TGR5 aggravates atherosclerosis in LDLR KO mice.

MATERIALS AND METHODS

Animals

FXR−/− and LDLR−/− mice on a C57BL/6J background were obtained from the Jackson Laboratory (4, 17). TGR5−/− mice on

Abbreviations: DKO, double KO; FXR, farnesoid X receptor; LDLR, LDL receptor; NF-κB, nuclear factor-κB; TGR5, G protein-coupled bile acid receptor 1; TKO, triple KO.

1 To whom correspondence should be addressed.

e-mail: makoto.miyazaki@ucdenver.edu

Journal of Lipid Research Volume 59, 2018 1709
FXR and TGR5 simultaneous deficiency induces atherosclerosis and blocks the anti-atherogenic effect of INT-767

We previously reported that a potent FXR and TGR5 dual agonist, INT-767, blocked the development of atherosclerosis in ApoE KO and LDLR KO mice (4). A number of previous studies have reported that either FXR or TGR5 single activation by specific agonists was sufficient to reduce the development of atherosclerosis in mouse models such as ApoE KO and LDLR KO mice (10, 11, 15). FXR and TGR5 single deficiency, however, was not sufficient to aggravate atherosclerosis in LDLR KO mice (12, 16). We have examined whether the anti-atherogenic effect of INT-767 requires activation of both FXR and TGR5 or whether one receptor is sufficient (Fig. 1). To determine which bile acid receptor mediates the anti-atherogenic effect of INT-767, 1) LDLR single KO mice, 2) FXR; LDLR double KO (FXR-DKO) mice, 3) TGR5; LDLR double KO (TGR5-DKO) mice, and 4) FXR; TGR5; LDLR triple KO (TKO) mice were treated with 30 mg/kg body weight INT-767. En face analysis clearly showed that FXR and TGR5 simultaneous deficiency remarkably aggravated atherosclerotic lesions of LDLR KO mice compared with LDLR KO, FXR-DKO, and TGR5-DKO (Fig. 1, A, B). Consistent with a previous report (16), FXR single deficiency slightly reduced atherosclerotic lesions ($P < 0.05$ using Student’s $t$ test), whereas TGR5 single deficiency did not affect atherosclerosis in LDLR KO mice (Fig. 1B). In addition, either FXR or TGR5 single deficiency did not affect the anti-atherogenic effect of INT-767. INT-767 treatment reduced atherosclerotic lesions by 84%, 75%, and 84% in LDLR KO, FXR-DKO, and TGR5-DKO mice, respectively (Fig. 1B). On the other hand, FXR and TGR5 deficiency abrogated the anti-atherogenic effect of INT-767 (Fig. 1A, B). These data demonstrate that the anti-atherogenic effect of INT-767 occurs through activation of both FXR and TGR5.

FXR mediates the lipid-lowering effect of INT-767

Consistent with our previous report (4), INT-767 elicited the potent lipid-lowering effect in male LDLR KO mice. Levels of serum total cholesterol, triacylglyceride, LDL-cholesterol, and HDL-cholesterol were reduced by 53%, 73%, 50%, and 39%, respectively, in LDLR KO mice treated with INT-767 (Fig. 1). TGR5 deficiency did not affect levels of serum lipids or the lipid-lowering effect of INT-767. INT-767 treatment reduced levels of serum total cholesterol, triacylglyceride, LDL-cholesterol, and HDL-cholesterol by 70%, 81%, 42%, and 33%. FXR-DKO and TKO mice had significantly higher levels of serum total cholesterol, triacylglycerides, and LDL-cholesterol compared with LDLR KO mice (Fig. 2). In addition, FXR single and FXR/TGR5 dual deficiency completely blocked the lipid-lowering effects of INT-767 (Fig. 2). These data suggest that INT-767 reduced serum lipids through FXR activation.
the attenuation of NFκB activation (4). In this study, we examined which bile acid receptor mediates the anti-inflammatory effect of INT-767. While FXR and TGR5 single deficiency did not alter mRNA levels of cytokine and chemokines, FXR and TGR5 dual deficiency drastically increased levels of aortic IL-1β, IL-6, TNFα, and MCP-1 by 7.4-fold, 15.9-fold, 6.9-fold, and 7.4-fold (Fig. 3A–D). INT-767 treatment significantly reduced mRNA levels of aortic IL-1β, IL-6, TNFα, and MCP-1 in LDLR KO, FXR-DKO, TGR5-DKO, and TKO mice, whereas FXR and TGR5 dual deficiency completely blocked the effect of INT-767 (Fig. 3A–D). Consistent with quantitative PCR analysis, immunofluorescence microscopic analysis showed that FXR and TGR5 simultaneous deficiency but not FXR or TGR5 single deficiency, significantly increased C68-macrophages and MCP-1 positive areas in atherosclerotic lesions of LDLR KO mice (Fig. 4A–C). Consistent with a previous report (4), INT-767 treatment reduced CD68-macrophages and MCP-1 positive areas in atherosclerotic lesions of LDLR KO mice. While FXR and TGR single deficiency did not affect CD68 and MCP-1 positive lesions, FXR and TGR5 simultaneous deficiency completely blocked the effect of INT-767 on macrophage infiltration and MCP-1 expression (Fig. 4A–C). We previously showed that the anti-inflammatory effect of INT-767 occurs through inhibition of the aortic NFκB pathway (4). INT-767 significantly reduced levels of active NFκB p65/p50 complexes in the aortas of LDLR KO mice (Fig. 4D). FXR and TGR5 simultaneous deficiency increased levels of aortic active NFκB and also blocked the effect of INT-767 (Fig. 4D).

**DISCUSSION**

We and other laboratories previously reported that treatment with an FXR and TGR5 dual bile acid receptor agonist, INT-767, reduced atherosclerotic lesions in murine models such as LDLR KO and ApoE KO mice (4, 7). In addition, INT-767 significantly reduced circulating lipids such as LDL-cholesterol and the expression of aortic inflammatory cytokines and chemokines through the inhibition of the NFκB pathway. However, because treatment with either FXR- or TGR5-specific agonists was sufficient to reduce the development of atherosclerosis in mouse models of atherosclerosis (10–12, 15), in this study, we examined which bile acid receptor activation mediates the anti-atherosclerotic effect, the lipid-lowering effect, and the anti-inflammatory effect of INT-767. Our current study clearly demonstrated that FXR and TGR5 simultaneous activation is required for the anti-atherosclerotic effect of INT-767. In addition, other bile acid-activated receptors, such as vitamin D receptor, pregnane X receptor, and muscarinic receptor (19–21), are not involved in the anti-atherosclerotic effect of INT-767.

The anti-atherosclerotic effect of INT-767 was not required to be present for the lipid-lowering effect to occur. While FXR sole deficiency was sufficient to block the lipid-lowering effect of INT-767, INT-767 was still able to reduce atherosclerotic formation in FXR-DKO mice, similar to LDLR KO mice. These results suggest that the presence of the anti-inflammatory effect of INT-767 is more crucial than the anti-atherosclerotic effect in order for the lipid-lowering effect of INT-767 to occur. Our previous in vitro studies and studies from others have suggested that the anti-inflammatory property of bile acids is mediated through TGR5 activation (4, 12). TGR5 is highly expressed in leukocytes such as macrophages (14), whereas FXR expression is low or undetectable in leukocytes (4, 16, 22). While FXR or TGR5 single deficiency did not affect the anti-inflammatory effect of INT-767, FXR and TGR5 simultaneous deficiency completely blocked the anti-inflammatory effect. Our data show that FXR and TGR5 activation both contribute to the anti-inflammatory effect of INT-767 in vivo. Because bone marrow cell transplants lacking both FXR and TGR5 did not induce atherosclerotic formation in irradiated LDLR KO mice (data not shown), we need to find tissues in which FXR and TGR5 activation is more critical for the development of atherosclerosis and aortic inflammation.

The current study is the first report showing that simultaneous inhibition of FXR and TGR5 is required for aggravating atherosclerotic formation in LDLR KO mice.
A number of studies have shown that either FXR or TGR5 sole activation is sufficient to reduce the development of atherosclerosis. Paradoxically, however, either FXR or TGR5 sole deficiency was not sufficient to aggravate atherosclerosis in several mouse models, including LDLR KO mice (16, 22). In addition, FXR sole deficiency decreased atherosclerotic formation in male LDLR KO mice (16). These results suggest that there are cross-talks, synergistic alterations, and compensatory alterations between FXR and TGR5 signaling. In the intestine, FXR activation leads to activation of TGR5 through the alteration of gut microbiota and their bile acid metabolites (23). These results suggest that subsequent and indirect activation of TGR5 by FXR activation and vice versa may be required for the anti-atherosclerotic effects of FXR- and TGR5-specific agonists to occur. Hyperlipidemia and inflammation are major hallmarks of atherosclerosis. TKO mice showed severe hyperlipidemia and aortic inflammation. However, as INT-767 inhibits atherosclerosis in the presence of hyperlipidemia in FXR-DKO mice, the induction of aortic NFκB-mediated inflammation is more crucial for accelerating atherosclerosis by FXR and TGR5 simultaneous deficiency.

Our current study made four major findings: 1) Lacking major bile acid signaling, FXR and TGR5 aggravate aortic NFκB-mediated inflammation and atherosclerosis, 2) simultaneous activation of FXR and TGR5 is required for the anti-atherosclerotic and anti-inflammatory effects of INT-767 to occur, 3) the lipid-lowering effect of INT-767 occurs solely through the activation of FXR and 4) the anti-inflammatory effect of INT-767 is more critical than the lipid-lowering effect for the anti-atherosclerotic effect of INT-767 to occur. Taken together, these findings suggest that targeting both FXR and TGR5 simultaneously may be more effective for treatment of atherosclerosis than targeting either receptor alone.

**Fig. 2.** FXR single deficiency is sufficient to block the lipid-lowering effect of INT-767. Mice were treated with INT-767 for 16 weeks. Total cholesterol (A), triacylglycerides (B), LDL-cholesterol (C), and HDL-cholesterol (D) of LDLR KO, FXR-DKO, TGR5-DKO, and TKO mice treated with INT-767. **P < 0.01, ***P < 0.001, ****P < 0.0001.

**Fig. 3.** FXR and TGR5 dual deficiency induces aortic cytokine and chemokine expression. Mice were treated with INT-767 for 16 weeks. mRNA levels of aortic IL-1β (A), IL-6 (B), TNFα (C), and MCP-1 (D) in LDLR KO, FXR-DKO, TGR5-DKO, and TKO mice treated with INT-767. mRNA levels were analyzed by RT-qPCR. *P < 0.01, ***P < 0.001.
The authors thank L. Adorini and M. Pruzanski (Intercept) for the INT-767 and G Vassileva (Merck) for the TGR5 knockout mice.

REFERENCES

1. Rizzo, G., D. Passeri, F. De Franco, G. Caccioli, L. Donadio, S. Orlandi, B. Sadeghpour, X. X. Wang, T. Jiang, M. Levi, et al. 2010. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol. Pharmacol. 78: 617–630.

2. Baghdasaryan, A., T. Claudel, J. Guinnhold, D. Silbert, L. Adorini, A. Roda, S. Vecchiotti, F. J. Gonzalez, K. Schoonjans, M. Strazzabosco, et al. 2011. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2−/− (Abcb4−/−) mouse cholangiopathy model by promoting biliary HCO output. Hepatology. 54: 1303–1312.

3. McMahan, R. H., X. X. Wang, L. L. Cheng, T. Krisko, M. Smith, K. El Kasmi, M. Pruzanski, L. Adorini, L. Golden-Mason, M. Levi, et al. 2013. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J. Biol. Chem. 288: 11761–11770.

4. Miyazaki-Anzai, S., M. Masuda, M. Levi, A. L. Keenan, and M. Miyazaki. 2014. Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis. PLoS One. 9:e90870.

5. Beli, E., Y. Yan, L. Moldovan, C. P. Vieira, R. Gao, Y. Duan, R. Prasad, A. Bhatwadekar, F. A. White, S. Townsend, et al. 2018. Restructuring of the gut microbiome by intermittent fasting prevents retinopathy and prolongs survival in db/db mice. Diabetes. Epub ahead of print. April 30, 2018; doi: 10.2337/db18-0158.

6. Roth, J. D., M. Feigh, S. S. Veidal, K. L. Fensholdt, K. T. Rigbolt, H. H. Hansen, L. C. Chen, M. Petitjean, W. Friley, N. Vrang, et al. 2018. INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsies-confirmed non-alcoholic steatohepatitis. World J. Gastroenterol. 24: 195–210.

7. JadHAV, K., Y. Xu, Y. Xu, Y. Li, J. Xu, Y. Zhu, L. Adorini, Y. K. Lee, T. Kasumov, L. Yin, et al. 2018. Reversal of metabolic disorders by intestine farnesoid X receptor agonist and the gut microbiota activates FXR and TGR5 dual deficiency induces NFκB-mediated inflammation. Mice were treated with INT-767 for 16 weeks. A: Representative picture of immunofluorescence analysis of MCP-1 in the aortas of LDLR KO and TGR5 KO mice treated with INT-767. Quantification of immunofluorescence analysis of MCP-1 (B) and CD68 (C) in the aortas of LDLR KO, FXR-DKO, TGR5-DKO, and TGR5 KO mice treated with INT-767. D: NFκB binding activity in the aortas of LDLR KO and TGR5 KO mice treated with INT-767. Treatment with either cold probe competitor or antibodies against p50/p65 completely blocked the specific binding of p50/p65 NFκB complex to the NFκB consensus oligonucleotide probe. **P < 0.01, ***P < 0.001.

8. Wang, X. X., D. Wang, Y. Luo, K. Miyakata, E. Dobrinshik, A. Z. Rosenberg, J. Levi, J. B. Kopp, A. Field, A. Hill, et al. 2018. FXR/TGR5 dual agonist prevents progression of nephropathy in diabetes and obesity. J. Am. Soc. Nephrol. 29: 118–137.

9. Hanniman, E. A., G. Lambert, T. C. McCarthy, and C. J. Sinal. 2005. Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J. Lipid Res. 46: 2505–2506.

10. Hartman, H. B., S. J. Gardell, C. J. Petucci, S. Wang, J. A. Krueger, and M. J. Evans. 2009. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR−/− and apoE−/− mice. J. Lipid Res. 50: 1090–1100.

11. Mencarelli, A., B. Renga, E. Distrutti, and S. Fiorucci. 2009. Antiatherosclerotic effect of farnesoid X receptor. Am. J. Physiol. Heart Circ. Physiol. 296: H1272–H1281.

12. Pols, T. W., M. Nomura, T. Harach, G. Lo Sasso, M. H. Oosterveer, C. Thomas, G. Rizzo, A. Gioiello, L. Adorini, R. Pellicciari, et al. 2011. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab. 14: 747–757.

13. Bookout, A. L., and D. J. Mangelsdorf. 2003. Quantitative real-time PCR protocol for analysis of nuclear receptor signaling pathways. Nucl. Recept. Signal. 1: e912.

14. Kawamata, Y., R. Fuji, M. Hosoya, M. Harada, H. Yoshida, M. Misa, S. Fukusumi, Y. Habata, T. Itoh, Y. Shimtani, et al. 2003. A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 278: 9435–9440.

15. Hambruch, E., S. Miyazaki-Anzai, U. Hahn, S. Matsu, A. Boettcher, S. Perovic-Ottstadt, T. Schluter, O. Kinzel, H. D. Krol, U. Deuschle, et al. 2012. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transepithelial cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (−/−) mice. J. Pharmacol. Exp. Ther. 343: 556–567.

16. Zhang, Y., X. Wang, C. Vales, F. Y. Lee, H. Lee, A. J. Lusis, and P. A. Edwards. 2006. FXR deficiency causes reduced atherosclerosis in LDLR−/− mice. Arterioscler. Thromb. Vasc. Biol. 26: 2216–2221.

17. Bookout, A. L., and D. J. Mangelsdorf. 2003. Quantitative real-time PCR protocol for analysis of nuclear receptor signaling pathways. Nucl. Recept. Signal. 1: e912.

18. Vassileva, G., A. Golovko, L. Markowitz, S. J. Abbondanzo, M. Zeng, S. Yang, L. Hoos, G. Tetzloff, D. Levitan, N. J. Murgolo, et al. 2006. Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. Biochem. J. 398: 425–430.

19. Staudinger, J. L., B. Goodwin, S. A. Jones, D. Hawkins-Brown, K. I. MacKenzie, A. LaTour, Y. Liu, C. D. Klaassen, K. K. Brown, J. Reinhard, et al. 2001. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. USA. 98: 3369–3374.

20. Makishima, M., T. T. Lu, W. Xie, G. K. Whitfield, H. Domoto, R. M. Evans, M. R. Haussler, and D. J. Mangelsdorf. 2002. Vitamin D receptor as an intestinal bile acid sensor. J. Lipid Res. 43: 77–84.

21. Guo, G. L., S. Santamaria-Fojio, T. E. Akiyama, M. J. Amar, B. J. Paiogen, B. Brewer, Jr., and F. J. Gonzalez. 2006. Effects of FXR in foam-cell formation and atherosclerosis development. Biochim. Biophys. Acta. 1761: 1401–1409.

22. Pathak, P., X. Gen, R. G. Nichols, J. M. Ferrell, S. Boehme, K. W. Krausz, A. D. Patterson, F. J. Gonzalez, and J. Y. L. Chiang. 2018. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism. Hepatology. Epub ahead of print. February 27, 2018; doi: 10.1002/hep.29857.

FXR and TGR5 in the regulation of atherosclerosis 1713